- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05461885
Value of Gym-based Exercise Training for Young Adults Receiving Antipsychotic Medication: The Vega Trial (Vega)
Value of Gym-based Exercise Training for Young Adults Receiving Antipsychotic Medication: A Pragmatic, Single-blinded, Multicenter Randomized Controlled Trial
This is a multicentre, pragmatic, randomised controlled trial to estimate the effect of a 4-month gym-based exercise training program on 1) patient-rated personal recovery (primary outcome), 2) Health-related quality of life, behavioral and functional symptoms, and cardiometabolic risk factors (secondary outcomes) in young adults with psychotic disorders.
Four-hundred antipsychotic-treated young adults (between the age of 18 and 35), who are capable to undertake an exercise program (potentially with a friend or family member where possible) will be recruited from outpatient treatment units and mental health services. Participants will be randomised to treatment as usual or exercise at a 2:1 ratio in favor of exercise. Outcomes will be measured at baseline and at 4, 6 and 12 months after randomisation, by researchers masked to participant allocation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
Antipsychotic medications are associated with development of metabolic side-effects. Patients with schizophrenia have a four-fold higher prevalence of metabolic syndrome, and a two-to-three-fold higher risk of cardiovascular diseases compared to the general population. These factors may contribute to the premature mortality of 15-20 years observed in people with schizophrenia. The increased morbidity and mortality in people with mental illness can be explained by several risk factors, including physical inactivity.
Evidence suggests that exercise can have beneficial effects on multiple cardiometabolic outcomes, and improve clinical symptoms, quality of life, global functioning, and reduce negative and depressive symptoms in people with schizophrenia. In general, greater effects are seen for higher doses of aerobic exercise and motivational theory-based interventions supervised by exercise professionals. However, because of strict inclusion criteria, the external validity of existing studies is limited, and effectiveness studies are urgently needed
Objectives:
The primary objective is to determine the effectiveness of participation in a four-month supervised, gym-based exercise program among people treated with antipsychotic medication compared to usual care on patient-rated recovery (primary outcome).
Secondary objectives are to examine if the gym-based exercise program compared to usual care improves the following:
- Mental health
- Health-related quality of life
- Behavioral and functional symptoms
- Metabolic health
As tertiary objectives, we will investigate if:
- Prolongation of subsidized gym membership in addition to motivational text messages (extended support) will be superior to subsidized gym membership alone (minimal support), and to treatment as usual in relation to post-intervention adoption of physical activity.
- The exercise program impacts the quality of life and physical and mental health of the participants' primary relative.
- Participation in the gym-based program is associated with a reduction in the participants' use of mental health care services.
- The exercise program is cost-effective.
Design:
This is a multi-center, pragmatic, randomized (1:2) superiority trial to compare a 4-month, supervised, gym-based exercise training program to usual care. The pragmatic nature of the trial entails that it is designed to evaluate the effectiveness of interventions in real-life routine practice conditions.
In order to explore different ways to support sustainment (i.e., post-intervention adherence/adoption of physical activity), and to guide strategies to facilitate adherence, we will do "a study within a trial" (SWAT). Hence participants randomized to the intervention at baseline, will be randomized (allocation ratio 1:1) after four months to minimal vs. extended support with regards to sustainment of physical activity.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aalborg, Denmark, 9220
- Aalborg University Hospital
-
Aarhus, Denmark, 8200
- Aarhus University Hospital
-
Copenhagen, Denmark, 2100
- Mental Health Centre Copenhagen
-
Glostrup Municipality, Denmark, 2600
- Mental Health Centre Glostrup
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- diagnosed with a psychotic disorder (F20-F29 Schizophrenia, schizotypal and delusional disorders) or an affective disorder (F30-F39 Mood [affective] disorders)
- able to read and speak Danish or English
Exclusion Criteria:
- advised from participating in exercise training by their treating doctor
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Vega Exercise Community
Participants will be offered one hour of tailored supervised, gym-based exercise training three times per week for a period of four months.
In addition, participants are offered free-of-charge membership to the gym for six months and are invited to take part in training classes and use fitness equipment provided by the gym to regular members.
The supervised program is tailored to meet the needs and requirements of this particular group of young adults and will include three weekly sessions of moderate-to-high intensity and mobility exercises.
|
The exercise sessions start with warm-up exercises, followed by 10-20 minutes resistance training (Part A), 10-20 minutes High Intensity Functional Training (HIFT) (Part B) and cool down.
Instructors are allowed to make local adjustments as the delivery of the intervention is considered pragmatic.
The participants can either perform the exercise together as one group, in pairs or one-by-one depending on individual needs and requests.
|
|
No Intervention: Usual care
Participants will receive treatment as usual and be informed of the official physical activity guidelines as part of the information on group allocation.
Moreover, they will be advised to continue their daily living, as they normally would do, not guiding them to other interventions neither preventing them to do so.
In addition, participants in the usual care group will be given a subsidized membership including access to the exercise classes for four months after the 12 months follow up.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Personal recovery
Time Frame: Baseline to four months
|
15-item Questionnaire about the Process of Recovery
|
Baseline to four months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Personal recovery
Time Frame: Baseline to six months and 12 months
|
15-item Questionnaire about the Process of Recovery
|
Baseline to six months and 12 months
|
|
Mental health
Time Frame: Baseline to four months
|
Mental Component Summary from the Short-Form 12 (SF-12) Health survey
|
Baseline to four months
|
|
Health-related quality of life
Time Frame: Baseline to four, six and 12 months
|
Short-Form 12 (SF-12) Health survey
|
Baseline to four, six and 12 months
|
|
Affective symptoms
Time Frame: Baseline to four, six and 12 months
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional distress
|
Baseline to four, six and 12 months
|
|
Physical Activity
Time Frame: Baseline to four, six and 12 months
|
International Physical Activity Questionnaire short form (IPAQ-SF)
|
Baseline to four, six and 12 months
|
|
Internalized Stigma
Time Frame: Baseline to four, six and 12 months
|
Internalized Stigma of Mental Illness Inventory (ISMI-9) short form
|
Baseline to four, six and 12 months
|
|
Use of substance (alcohol, cannabis, drugs)
Time Frame: Baseline to four, six and 12 months
|
Measured by self-developed items with responses for each substance: "never used", "use less than once a month", "regular use", "harmful use"
|
Baseline to four, six and 12 months
|
|
Sleep
Time Frame: Baseline to four, six and 12 months
|
Brief Pittsburgh Sleep Quality Index (B-PSQI)
|
Baseline to four, six and 12 months
|
|
Positive and negative symptoms
Time Frame: Baseline to four, six and 12 months
|
Colorado Symptom Index (MCSI)
|
Baseline to four, six and 12 months
|
|
Loneliness
Time Frame: Baseline to four, six and 12 months
|
Measured by a single item on a Likert scale of 4 levels: "During the past 12 months, have you felt lonely?"
|
Baseline to four, six and 12 months
|
|
Abdominal circumference
Time Frame: Baseline to four, six and 12 months
|
Measured with tape measure
|
Baseline to four, six and 12 months
|
|
Body weight
Time Frame: Baseline to four, six and 12 months
|
Measured on a scale
|
Baseline to four, six and 12 months
|
|
Skeletal muscle mass
Time Frame: Baseline to four, six and 12 months
|
Measured by bioimpedance
|
Baseline to four, six and 12 months
|
|
Total body fat
Time Frame: Baseline to four, six and 12 months
|
Measured by bioimpedance
|
Baseline to four, six and 12 months
|
|
Cardiorespiratory fitness
Time Frame: Baseline to four, six and 12 months
|
measured with the modified Ekblom-Bak submaximal cycle ergometer test
|
Baseline to four, six and 12 months
|
|
Blood pressure
Time Frame: Baseline to four, six and 12 months
|
measured by a digital blood pressure monitor
|
Baseline to four, six and 12 months
|
|
Resting heart rate
Time Frame: Baseline to four, six and 12 months
|
measured by a heart rate monitor
|
Baseline to four, six and 12 months
|
|
High density lipoproteins (HDL)
Time Frame: Baseline to four, six and 12 months
|
Taken from routine blood tests (mmol/l)
|
Baseline to four, six and 12 months
|
|
Low density lipoproteins (LDL)
Time Frame: Baseline to four, six and 12 months
|
Taken from routine blood tests (mmol/l)
|
Baseline to four, six and 12 months
|
|
Triglycerides
Time Frame: Baseline to four, six and 12 months
|
Taken from routine blood tests (mmol/l)
|
Baseline to four, six and 12 months
|
|
Glycosylated haemoglobin (HbA1c)
Time Frame: Baseline to four, six and 12 months
|
Taken from routine blood tests (mmol/l)
|
Baseline to four, six and 12 months
|
|
C-reactive protein (CRP)
Time Frame: Baseline to four, six and 12 months
|
Taken from routine blood tests (mg/L)
|
Baseline to four, six and 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Use of the subsidized membership
Time Frame: four to six months
|
To explore if prolongation of subsidized gym membership in addition to motivational text messages (extended support) is superior to subsidized gym membership alone (minimal support), and to treatment as usual in relation to post-intervention adoption of physical activity measured by use of the subsidized membership (intervention group only)
|
four to six months
|
|
Extended vs. minimal support for physical activity
Time Frame: four to six months
|
To explore if prolongation of subsidized gym membership in addition to motivational text messages (extended support) is superior to subsidized gym membership alone (minimal support), and to treatment as usual in relation to post-intervention adoption of physical activity measured by the IPAQ-SF (both groups).
|
four to six months
|
|
Quality of life of primary relatives to participants
Time Frame: Baseline to four, six and 12 months
|
To explore the impact of the Vega Exercise Community on the quality of life measured by SF-12 of the participants' primary relative
|
Baseline to four, six and 12 months
|
|
Sleep of primary relatives to participants
Time Frame: Baseline to four, six and 12 months
|
To explore the impact of the Vega Exercise Community on sleep (measured by B-PSQI) of the participants' primary relative
|
Baseline to four, six and 12 months
|
|
Mental health of primary relatives to participants
Time Frame: Baseline to four, six and 12 months
|
To explore the impact of the Vega Exercise Community on mental health (measured by PROMIS Emotional Distress-Depression - Short Form 4a) of the participants' primary relative
|
Baseline to four, six and 12 months
|
|
Physical activity of primary relatives to participants
Time Frame: Baseline to four, six and 12 months
|
To explore the impact of the Vega Exercise Community on physical activity (measured by IPAQ-SF) of the participants' primary relative
|
Baseline to four, six and 12 months
|
|
Utilization of mental health care services
Time Frame: 24 months and 60 months
|
To explore differences between groups of participants' long-term use of mental health care services, specifically number of inpatient and outpatient mental health contacts, including mental health emergency departments obtained from medical records
|
24 months and 60 months
|
|
Cost of the Vega Exercise Community
Time Frame: Baseline to four, six and 12 months
|
To explore the intervention cost i.e., education of instructors and delivery of exercise classes
|
Baseline to four, six and 12 months
|
|
Cost-effectiveness of the Vega Exercise Community
Time Frame: Baseline to four, six and 12 months
|
To explore the cost-effectiveness by comparing the cost and health-related quality of life, which will be measured by the EuroQol-5 Domain (EQ-5D)
|
Baseline to four, six and 12 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Vega Trial
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychosis
-
Columbia UniversityNational Institute of Mental Health (NIMH); University of California, Davis; University... and other collaboratorsRecruitingClinical High Risk | First Episode Psychosis | Early PsychosisUnited States
-
University of OxfordWellcome Trust; Jazz PharmaceuticalsNot yet recruitingClinical High Risk for Psychosis | Clinical High Risk for Psychosis (CHR) | Clinical High Risk for Developing PsychosisUnited Kingdom, Italy, Greece, Finland, Germany, Netherlands, Austria, Canada, Spain, Switzerland
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)Enrolling by invitationFirst Episode Psychosis (FEP) | Clinical High Risk for Psychosis (CHR)United States
-
University of New MexicoNational Institute of Mental Health (NIMH)CompletedPsychosis | Clinical High Risk for Psychosis | First Episode PsychosisUnited States
-
Columbia UniversityNational Institute of Mental Health (NIMH)RecruitingClinical High Risk | First Episode Psychosis | Early PsychosisUnited States
-
Elazığ Mental Health and Diseases HospitalRecruitingMethamphetamine Induced PsychosisTurkey (Türkiye)
-
Shanghai Jiao Tong University School of MedicineGuangzhou Psychiatric Hospital; Suzhou Psychiatric Hospital; Tianjin Anding Hospital and other collaboratorsRecruitingSchizophrenia; Psychosis | Clinical High Risk | First Episode PsychosisChina
-
University of OxfordHospital General Universitario Gregorio Marañon; Charite University, Berlin... and other collaboratorsNot yet recruitingPsychosis | Treatment Resistant PsychosisSpain, United Kingdom, Germany, Israel, Greece, Italy, Netherlands, Switzerland
-
Chulalongkorn UniversityNational Research Council of Thailand; Thanyarak InstituteCompletedMethamphetamine-induced PsychosisThailand
-
Université de SherbrookeBaszucki Brain Research FundNot yet recruitingMetabolic Disease | Psychosis; Episode | First Episose PsychosisCanada
Clinical Trials on Supervised exercise
-
Hull University Teaching Hospitals NHS TrustCompletedAbdominal Aortic AneurysmUnited Kingdom
-
University of ManchesterUnknownCardiovascular Diseases | Peripheral Arterial Disease
-
University of SevilleUniversity Hospital Virgen del Rocio, SevillaNot yet recruitingPhysical Activity | Exercise | Abdominal Wall Hernia | Prevention
-
Universidad de AlmeriaCompletedLow Back Pain | Physical ActivitySpain
-
Medical University of ViennaUnknownPeripheral Artery DiseaseAustria
-
Hasselt UniversityRecruitingGestational Hypertension | Cardiovascular Pregnancy ComplicationBelgium
-
Grupo Rehabilitacion en SaludClinica Las AmericasCompletedChronic Heart FailureColombia
-
University Health Network, TorontoCompletedProstate CancerCanada
-
Ahram Canadian UniversityRecruiting
-
Northwestern Health Sciences UniversityHealth Resources and Services Administration (HRSA); Berman Center for Outcomes...Completed